These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17701003)

  • 21. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
    Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
    Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
    Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
    J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
    Takami M; Kita E; Kuwana Y; Ohta Y; Nakayama Y; Fukai H; Matsumoto H; Takimoto T; Ichikawa G; Yamamoto T
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1243-5. PubMed ID: 18633273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
    Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
    Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
    Hirakawa H; Futagami M; Yokoyama Y; Hakamada K; Mizunuma H
    Gan To Kagaku Ryoho; 2011 May; 38(5):857-60. PubMed ID: 21566454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
    Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
    Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
    du Bois A; Lück HJ; Meier W; Adams HP; Möbus V; Costa S; Bauknecht T; Richter B; Warm M; Schröder W; Olbricht S; Nitz U; Jackisch C; Emons G; Wagner U; Kuhn W; Pfisterer J;
    J Natl Cancer Inst; 2003 Sep; 95(17):1320-9. PubMed ID: 12953086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
    Zhao XD; Zhang Y; He SR; Yang L
    Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinosarcoma of the ovary-a case series.
    Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
    Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.